The global non muscle invasive bladder cancer market size is expected to be USD 371.1 Million in 2025. It is expected to reach a valuation of USD 656.9 Million by 2032. The market is anticipated to exhibit a CAGR of 8.5% during the forecast period (2025-2032).  

The rising prevalence of bladder cancer cases, namely non muscle invasive bladder cancer (NMIBC), advanced diagnostic tests, and approval for intravesical agents can drive the market growth.

However, the different tumor grades of NMIBC and varied responses to advanced therapeutic drugs across populations are challenges for the market.

Key Market Insights

The non muscle invasive bladder cancer market is anticipated to expand owing to the use of chemotherapy agents, approval of neoantigen vaccines, and rise of combination therapies.

• By treatment type, the chemotherapy segment is likely to score a significant share of the market in 2025. This can be attributed to the treatment given to NMIBC in its early stages. The use of intravesical chemotherapy to patients with recurring instances of bladder cancer can drive the segment growth during the forecast period.
• By disease stage, the stage 0is segment is predicted to capture a robust market share in 2025. This is owing to alarming cases of carcinoma in situ (CIS), the second stage of bladder cancer. This is illustrated by ImmunityBio’s nogapendekin alfa inbakicept-pmln (ANKITVA) in combination with Bacillus Calmette-Guérin (BCG) therapy being granted marketing authorization by the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) to the U.S. on July 07, 2025.
• By region, Europe is expected to contribute significantly to the non muscle invasive bladder cancer market over the forecast period. This can be attributed to the approval of advanced therapy medicinal products (ATMPs) by the European Medicine Agency and reimbursement schemes for urine tests. The development of AI tools for the prediction and management of NMIBC can elevate the growth share of the market.

The full report is now available for purchase: https://www.coherentmi.com/industry-reports/non-muscle-invasive-bladder-cancer-market

Non Muscle Invasive Bladder Cancer Market Report Coverage

Market Dynamics

The efficacy of intravesical chemotherapy is one of the major drivers of the non muscle invasive bladder cancer market. The need for intensive monitoring and management for the elimination of NMIBC has propelled the use of intravesical chemotherapy. Sequential intravesical valrubicin and docetaxel had a good outcome on the patients undergoing chemotherapy. As per a study published in European Urology Focus on June 26, 2025, nearly half of the patients were disease-free after 2 years.

The focus on high-risk and intermediate-risk NMIBC by pharmaceutical companies can augur favorably for the market. The development of a strong pipeline, streamlined operational facilities, and minimally invasive surgeries are drivers that can boost market growth. On October 03, 2024, Ferring Pharmaceuticals inaugurated a new European manufacturing site in Kuopio, Finland. The site will focus on the manufacture of the drug substance of its gene therapy, Adstiladrin (nadofaragene firadenovec-vncg).

Market Opportunity: Use of Gel Formulations to Ease Chemotherapy Pain

The tolerance level of patients undergoing chemotherapy varies and has a prime impact on the patient outcome levels. The development of intravesical drug delivery systems containing drug formulations such as UGN-102 and TAR-200 for delivery at the targeted area can drive the non muscle invasive bladder cancer market growth. These anti-cancer agents used in tandem with chemotherapy can be crucial in driving advancements in NMIBC care. On June 13, 2025, Zusduri was approved for marketing in the U.S. by the FDA and should be available by July of the same year. The gel-based formulation keeps chemotherapy within the bladder to prolong its effect and eliminate the probability of metastasis.

Market Challenge: Low Number of Patients Qualified for Clinical Trial Participation

The large number of therapies being developed for the treatment of NMIBC has led to many patients being unable to participate in early trials. While the number of options available is a good thing, the lack of timely treatment and clinical trials for a small and narrow population may limit the drug’s use. This can impede the global market growth and hamper the development of novel drugs. The focus on BCG alternative therapies and approval of novel drugs at economical costs can upend this challenge.

Analyst’s View

• The incorporation of novel drugs alongside chemotherapy for treating NMIBC in the elderly population is expected to drive growth in the non muscle invasive bladder cancer market.
• The chemotherapy segment is anticipated to scale over the forecast period. Approval of new gels and drugs that keep chemotherapy within the system to eradicate persistent tumors can drive the segment growth.
• Key players are ramping up their manufacturing capacity globally by building new facilities to keep the supply intact.

Recent Developments

Detalimogene, a novel gene-based immunotherapy developed by enGene, was granted RMAT designation by the U.S. FDA for the treatment of NMIBC on June 26, 2025. The phase 2 LEGEND trial displayed a 71% complete response rate in Bacillus Calmette Guérin (BCG)-unresponsive NMIBC.

Competitor Insights

• Merck & Co., Inc.
• Pfizer Inc.
• CG Oncology
• Ferring Pharmaceuticals
• Sesen Bio, Inc.

Market Segmentation

• By Treatment Type
• BCG Therapy
• Chemotherapy
• Immunotherapy
• By Disease Stage
• Stage 0a
• Stage 0is
• Stage I

Regional Insights

• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Italy
  • Germany
  • U.K.
  • Spain
  • Russia
  • France
  • Rest of Europe
• Asia Pacific
  • South Korea
  • India
  • China
  • Japan
  • Australia
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa